Adial Pharmaceuticals Stock Performance
| ADIL Stock | USD 0.77 0.02 2.53% |
The firm shows a Beta (market volatility) of -0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Adial Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Adial Pharmaceuticals is likely to outperform the market. At this point, Adial Pharmaceuticals has a negative expected return of -0.36%. Please make sure to confirm Adial Pharmaceuticals' total risk alpha and the relationship between the skewness and period momentum indicator , to decide if Adial Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Adial Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in March 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Last Split Factor 1:25 | Last Split Date 2023-08-07 |
1 | Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence ... | 12/03/2024 |
2 | Acquisition by Claiborne Cary J of 350000 shares of Adial Pharmaceuticals at 1.15 subject to Rule 16b-3 | 12/05/2024 |
3 | Adial Pharmaceuticals New Purchase Agreement with Alumni Capital - TipRanks | 12/18/2024 |
4 | ADIL Stock Earnings Adial Pharmaceuticals Misses EPS for Q1 2024 - MSN | 01/14/2025 |
5 | EXCLUSIVE Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder | 01/29/2025 |
6 | Disposition of 8649 shares by Schuyler Kevin of Adial Pharmaceuticals at 7.63 subject to Rule 16b-3 | 02/11/2025 |
7 | Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of ... | 02/12/2025 |
8 | Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach ... | 02/19/2025 |
| Begin Period Cash Flow | 4 M |
Adial |
Adial Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 99.00 in Adial Pharmaceuticals on November 27, 2024 and sell it today you would lose (22.00) from holding Adial Pharmaceuticals or give up 22.22% of portfolio value over 90 days. Adial Pharmaceuticals is currently does not generate positive expected returns and assumes 3.8411% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Adial, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adial Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adial Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adial Pharmaceuticals, and traders can use it to determine the average amount a Adial Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0933
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ADIL |
Estimated Market Risk
| 3.84 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.36 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Adial Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adial Pharmaceuticals by adding Adial Pharmaceuticals to a well-diversified portfolio.
Adial Pharmaceuticals Fundamentals Growth
Adial Stock prices reflect investors' perceptions of the future prospects and financial health of Adial Pharmaceuticals, and Adial Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adial Stock performance.
| Return On Equity | -3.17 | ||||
| Return On Asset | -1.06 | ||||
| Current Valuation | 2.73 M | ||||
| Shares Outstanding | 6.47 M | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 0.86 X | ||||
| EBITDA | (7 M) | ||||
| Net Income | (7 M) | ||||
| Cash And Equivalents | 9.16 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 653.08 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.32 X | ||||
| Book Value Per Share | 0.92 X | ||||
| Cash Flow From Operations | (6.81 M) | ||||
| Earnings Per Share | (2.94) X | ||||
| Market Capitalization | 4.95 M | ||||
| Total Asset | 4.74 M | ||||
| Retained Earnings | (68.8 M) | ||||
| Working Capital | 2.99 M | ||||
| Current Asset | 1.02 M | ||||
| Current Liabilities | 452.53 K | ||||
About Adial Pharmaceuticals Performance
By examining Adial Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Adial Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Adial Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.33) | (1.40) | |
| Return On Capital Employed | (1.94) | (2.04) | |
| Return On Assets | (1.33) | (1.40) | |
| Return On Equity | (1.97) | (2.07) |
Things to note about Adial Pharmaceuticals performance evaluation
Checking the ongoing alerts about Adial Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adial Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adial Pharmaceuticals generated a negative expected return over the last 90 days | |
| Adial Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Adial Pharmaceuticals has high historical volatility and very poor performance | |
| Adial Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Adial Pharmaceuticals currently holds about 9.16 M in cash with (6.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. | |
| Latest headline from gurufocus.com: Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach ... |
- Analyzing Adial Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adial Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Adial Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adial Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adial Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adial Pharmaceuticals' stock. These opinions can provide insight into Adial Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.